Challenges in Genetic Testing and Treatment Outcomes Among Hispanics With Lung Cancer

Raez, Luis E.; Zorrilla, Andrés Felipe Cardona; Lopes, Gilberto; Arrieta, Óscar

doi:10.1200/op.22.00096

Cited by 3 publications

(2 citation statements)

References 30 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obtaining germline data may lead to the development of improved genetic screening strategies and management options for patients. Considerations should be made for barriers to precision care for patients in the Hispanic/Latinx community, who may experience differences in access to care, health insurance, and immigration status [ 60 ]. Finally, proactive surveillance may be beneficial for the family of patients with NSCLC harboring PGVs in cancer-predisposing genes.…”

Section: Discussionmentioning

confidence: 99%

Characterization of Incidental Pathogenic Germline Findings Detected via ctDNA among Patients with Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population

Vallabhaneni,

Kareff,

Barnett

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

Pathogenic germline variants (PGVs) may be under-detected as causative etiologies in patients with non-small cell lung cancer (NSCLC). The prevalence of PGVs has been reported between 1 and 15% of patients, depending on the patient population. The rate within Hispanic/Latinx populations remains unknown. We retrospectively analyzed the genomic results (Guardant360, Redwood City, CA, USA) of 878 patients with advanced or metastatic NSCLC at five centers in South Florida, USA, from 2019 to 2022 to analyze the rate of incidental PGVs (iPGVs) identified via circulating cell-free tumor DNA (ctDNA). We then stratified the results by tumor histology, age, gender, race, ethnicity, genetic pathway, and co-mutations. Twenty-one iPGVs were identified (21/878 = 2.4%). Among the 21 iPGVs identified, 14 patients were female (66.7%) and 7 were male (33.3%), with a median age of 67 years and tobacco history of 2.5 pack-years. In total, 52.4% of patients identified as Hispanic/Latinx (n = 11) of any race; 19.0% as Ashkenazi Jewish (n = 4), 9.5% as non-Hispanic/Latinx black (n = 2), and 19.0% as non-Hispanic/Latinx white (n = 4). iPGVs in the homologous recombination repair pathway were solely expressed in this cohort (10 ATM, 8 BRCA2, and 3 BRCA1). In total, 76% (16/21) of patients with iPGVs co-expressed somatic alterations, with 56% (9/16) demonstrating alterations in targetable genes. Overall, our real-world findings offer a point prevalence of iPGVs in patients with NSCLC of diverse populations, such as patients who report Hispanic/Latinx ethnicity.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization of Incidental Pathogenic Germline Findings Detected via ctDNA among Patients with Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population

Vallabhaneni,

Kareff,

Barnett

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…The issue expands knowledge on focused topics such as disparities in cardio-oncology care as reviewed by Suero-Abreu et al 8 with potential solutions to improve care. Differences in genetic variants in the Hispanic/Latinx patient population were observed through the genetic counseling efforts of Soewito et al 9 In their editorial, Raez et al 10 outlined some of the ongoing challenges in genetic testing and treatment outcomes in patients with lung cancer. In addition, the importance of cancer care communication was a welcomed addition to the series by Ochoa et al, 11 with their focus on the young adult childhood cancer survivors, their parents, and health care teams.…”

mentioning

confidence: 99%

Disparities in Cancer Care and Scientific Knowledge in Hispanic/Latinx People in the United States

Bosserman

Duma²,

Villalona‐Calero

et al. 2022

JCO Oncology Practice

Self Cite

View full text Add to dashboard Cite

LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer

et al. 2022

View full text Add to dashboard Cite

(1) Background: Liver kinase B1 (LKB1) is a tumor suppressor gene involved in cell growth and metabolism. However, its alterations are not routinely assessed for guiding therapy in clinical practice. We assessed LKB1 expression by immunohistochemistry as a potential biomarker. (2) Methods: This bicentric retrospective cohort study analyzed data from patients with advanced NSCLC who initiated platinum-based chemotherapy or epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) between January 2016 and December 2020. Kaplan–Meier and Cox regression models were used for survival curves and multivariate analysis. (3) Results: 110 patients were evaluated, and the clinical stage IV predominated the lung adenocarcinoma histology. LKB1 loss was observed in 66.3% of cases. LKB1 loss was associated with non-smokers, the absence of wood smoke exposure and an EGFR wild-type status. The median progression-free survival (PFS) and overall survival (OS) in the population were 11.1 and 26.8 months, respectively, in the loss group, compared with cases exhibiting a positive expression. After an adjustment by age, smoking status, Eastern Cooperative Oncology Group Performance Score (ECOG-PS), EGFR status and type of administered therapy, LKB1 loss was significantly associated with worse PFS and OS. (4) Conclusion: Patients with an LKB1 loss had worse clinical outcomes. This study warrants prospective assessments to confirm the prognostic role of the LKB1 expression in advanced NSCLC.

show abstract

Challenges in Genetic Testing and Treatment Outcomes Among Hispanics With Lung Cancer

Cited by 3 publications

References 30 publications

Characterization of Incidental Pathogenic Germline Findings Detected via ctDNA among Patients with Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population

Characterization of Incidental Pathogenic Germline Findings Detected via ctDNA among Patients with Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population

Disparities in Cancer Care and Scientific Knowledge in Hispanic/Latinx People in the United States

LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer

Contact Info

Product

Resources

About